- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023
An examination of data presented at ESMO 2023 from cohort 1 of the THOR-2 study of high-risk non–muscle invasive bladder cancer (HR NMIBC) with FGFR alterations.
EP: 1.Biomarkers and Molecular/ Genomic Testing in Genitourinary Cancers
EP: 2.Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023
EP: 3.Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape
EP: 4.ESMO 2023 Insights: SunRISe-1 Study of TAR-200 in BCG-Unresponsive Bladder Cancer
EP: 5.Key Highlights from EV-302 Study at ESMO 2023
EP: 6.LITESPARK-003 Trial Insights: Updates from ESMO 2023
EP: 7.Future Opportunities in Genitourinary Cancers
This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD.
Daneshmand discusses results from the THOR-2 study of erdafitinib for BCG-refractory non–muscle invasive bladder cancer with FGFR (fibroblast growth factor receptor) alterations. Patients were randomly assigned 2:1 to receive oral erdafitinib 6 mg daily or investigator’s choice of intravesical chemotherapy. The primary end point was recurrence-free survival (RFS), with secondary end points of 6-month and 12-month RFS.
With median 13-month follow-up, median RFS was not reached with erdafitinib versus 0.28 for chemotherapy, favoring erdafitinib. The 12-month RFS was 77% with erdafitinib versus 41% with chemotherapy. Erdafitinib significantly reduced recurrence in high-risk patients. However, most patients experienced treatment-related adverse events with the oral formulation.
Daneshmand notes that while erdafitinib showed efficacy, the oral toxicity profile is concerning for non–muscle invasive bladder cancer treatment. This paved the way for the TAR-200 study using an intravesical formulation of erdafitinib, which will be discussed later.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
December 3rd 2025The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.
Read More
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
